ASKG193 / Aosaikang Pharma - LARVOL DELTA

ASKG193, a novel masked CD19 T-cell engager exhibited potency and expanded safety (SITC 2025) - "In addition, ASKG193 was well tolerated in vivo.Conclusions In summary, the masked CD19 TCE, ASKG193, exhibited superior anti-tumor efficacy, prolonged half-life, and a significantly improved safety profile. Our data demonstrated that the ASKG193 has the potential to substantially broaden the therapeutic window for CD19-targeted immunotherapies."

Clinical • Oncology